• 1
    Halder SL, Locke GR, Talley NJ et al. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 23342.
  • 2
    McKendrick MW, Read NW. Irritable bowel syndrome – post-Salmonella infection. J Infect 1994; 29: 13.
  • 3
    Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 1503.
  • 4
    Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 4006.
  • 5
    Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. Br Med J 1999; 318: 5656.
  • 6
    Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997; 314: 77982.
  • 7
    Parry SD, Stansfield R, Jelley D et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98: 19705.
  • 8
    Hiatt RB, Katz L. Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 1962; 37: 5415.
  • 9
    Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096101.
  • 10
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 11
    Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 5236.
  • 12
    Collins SM. Irritable bowel syndrome could be an inflammatory disorder. Eur J Gastroenterol Hepatol 1994; 6: 47881.
  • 13
    Barbara G, De Giorgio R, Stanghellini V et al. A role for inflammation in irritable bowel syndrome? Gut 2002; 51: 414.
  • 14
    Dunlop SP, Jenkins D, Neal KR et al. Randomised, double blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 7784.
  • 15
    Parry S, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastro-intestinal diseases (FGID's): does smoking play a role? Eur J Gastroenterol Hepatol 2005; 17: 10715.
  • 16
    British Thoracic Society Standards of Care. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56: 164.
  • 17
    Drossman DA, Corazziari E, Talley NJ et al. Rome II Modular Questionnaire – Investigator and Respondent Forms. In Drossman DA, Corazziari E, Talley NJ et al. (Eds) Rome II: the Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus, 2nd edn. USA: Allen Press, 2000.